133 related articles for article (PubMed ID: 23933442)
21. Lung-specific delivery of paclitaxel by chitosan-modified PLGA nanoparticles via transient formation of microaggregates.
Yang R; Yang SG; Shim WS; Cui F; Cheng G; Kim IW; Kim DD; Chung SJ; Shim CK
J Pharm Sci; 2009 Mar; 98(3):970-84. PubMed ID: 18661542
[TBL] [Abstract][Full Text] [Related]
22. Folic acid-coupled nano-paclitaxel liposome reverses drug resistance in SKOV3/TAX ovarian cancer cells.
Tong L; Chen W; Wu J; Li H
Anticancer Drugs; 2014 Mar; 25(3):244-54. PubMed ID: 24275314
[TBL] [Abstract][Full Text] [Related]
23. Alpha-tocopheryl polyethylene glycol succinate-emulsified poly(lactic-co-glycolic acid) nanoparticles for reversal of multidrug resistance in vitro.
Wang Y; Guo M; Lu Y; Ding LY; Ron WT; Liu YQ; Song FF; Yu SQ
Nanotechnology; 2012 Dec; 23(49):495103. PubMed ID: 23149859
[TBL] [Abstract][Full Text] [Related]
24. Preparation, characterization, and in vivo study of rhein-loaded poly(lactic-co-glycolic acid) nanoparticles for oral delivery.
Yuan Z; Gu X
Drug Des Devel Ther; 2015; 9():2301-9. PubMed ID: 25960633
[TBL] [Abstract][Full Text] [Related]
25. Effects of poly(ethylene glycol) grafting density on the tumor targeting efficacy of nanoparticles with ligand modification.
Zhang S; Tang C; Yin C
Drug Deliv; 2015 Feb; 22(2):182-90. PubMed ID: 24215373
[TBL] [Abstract][Full Text] [Related]
26. Enabling anticancer therapeutics by nanoparticle carriers: the delivery of Paclitaxel.
Liu Y; Zhang B; Yan B
Int J Mol Sci; 2011; 12(7):4395-413. PubMed ID: 21845085
[TBL] [Abstract][Full Text] [Related]
27. CS/PAA@TPGS/PLGA nanoparticles with intracellular pH-sensitive sequential release for delivering drug to the nucleus of MDR cells.
Wang YY; Zhang DD; Kong YY; Shao LL; Zhang FY; Gao Y; Mu X; Wang J; Li HF; Yu SQ; Xu Q
Colloids Surf B Biointerfaces; 2016 Sep; 145():716-727. PubMed ID: 27289313
[TBL] [Abstract][Full Text] [Related]
28. Translocator protein ligand-PLGA conjugated nanoparticles for 5-fluorouracil delivery to glioma cancer cells.
Laquintana V; Denora N; Lopalco A; Lopedota A; Cutrignelli A; Lasorsa FM; Agostino G; Franco M
Mol Pharm; 2014 Mar; 11(3):859-71. PubMed ID: 24410438
[TBL] [Abstract][Full Text] [Related]
29. A novel technique for loading of paclitaxel-PLGA nanoparticles onto ePTFE vascular grafts.
Lim HJ; Nam HY; Lee BH; Kim DJ; Ko JY; Park JS
Biotechnol Prog; 2007; 23(3):693-7. PubMed ID: 17465527
[TBL] [Abstract][Full Text] [Related]
30. Preparation and characterization of insulin-loaded bioadhesive PLGA nanoparticles for oral administration.
Zhang X; Sun M; Zheng A; Cao D; Bi Y; Sun J
Eur J Pharm Sci; 2012 Apr; 45(5):632-8. PubMed ID: 22248882
[TBL] [Abstract][Full Text] [Related]
31. Enhancement of the targeting capabilities of the Paclitaxel-loaded pluronic nanoparticles with a glycol chitosan/heparin composite.
Yuk SH; Oh KS; Cho SH; Kim SY; Oh S; Lee JH; Kim K; Kwon IC
Mol Pharm; 2012 Feb; 9(2):230-6. PubMed ID: 22149139
[TBL] [Abstract][Full Text] [Related]
32. Mesenchymal stromal cells loaded with paclitaxel induce cytotoxic damage in glioblastoma brain xenografts.
Pacioni S; D'Alessandris QG; Giannetti S; Morgante L; De Pascalis I; Coccè V; Bonomi A; Pascucci L; Alessandri G; Pessina A; Falchetti ML; Pallini R
Stem Cell Res Ther; 2015 Oct; 6():194. PubMed ID: 26445228
[TBL] [Abstract][Full Text] [Related]
33. Self-assembled biodegradable nanoparticles developed by direct dialysis for the delivery of paclitaxel.
Xie J; Wang CH
Pharm Res; 2005 Dec; 22(12):2079-90. PubMed ID: 16132339
[TBL] [Abstract][Full Text] [Related]
34. Poly(D,L-lactide-co-glycolide) (PLGA) nanoparticles prepared by high pressure homogenization for paclitaxel chemotherapy.
Dong Y; Feng SS
Int J Pharm; 2007 Sep; 342(1-2):208-14. PubMed ID: 17560058
[TBL] [Abstract][Full Text] [Related]
35. Enhanced electrostatic interaction between chitosan-modified PLGA nanoparticle and tumor.
Yang R; Shim WS; Cui FD; Cheng G; Han X; Jin QR; Kim DD; Chung SJ; Shim CK
Int J Pharm; 2009 Apr; 371(1-2):142-7. PubMed ID: 19118614
[TBL] [Abstract][Full Text] [Related]
36. Surface modification of PLGA nanoparticles with biotinylated chitosan for the sustained in vitro release and the enhanced cytotoxicity of epirubicin.
Chen H; Xie LQ; Qin J; Jia Y; Cai X; Nan W; Yang W; Lv F; Zhang QQ
Colloids Surf B Biointerfaces; 2016 Feb; 138():1-9. PubMed ID: 26638176
[TBL] [Abstract][Full Text] [Related]
37. Paclitaxel-loaded PLGA nanoparticles surface modified with transferrin and Pluronic((R))P85, an in vitro cell line and in vivo biodistribution studies on rat model.
Shah N; Chaudhari K; Dantuluri P; Murthy RS; Das S
J Drug Target; 2009 Aug; 17(7):533-42. PubMed ID: 19530913
[TBL] [Abstract][Full Text] [Related]
38. β-casein nanovehicles for oral delivery of chemotherapeutic Drug combinations overcoming P-glycoprotein-mediated multidrug resistance in human gastric cancer cells.
Bar-Zeev M; Assaraf YG; Livney YD
Oncotarget; 2016 Apr; 7(17):23322-34. PubMed ID: 26989076
[TBL] [Abstract][Full Text] [Related]
39. Mesenchymal stem cells: a potential targeted-delivery vehicle for anti-cancer drug, loaded nanoparticles.
Gao Z; Zhang L; Hu J; Sun Y
Nanomedicine; 2013 Feb; 9(2):174-84. PubMed ID: 22772046
[TBL] [Abstract][Full Text] [Related]
40. Wheat germ agglutinin-conjugated PLGA nanoparticles for enhanced intracellular delivery of paclitaxel to colon cancer cells.
Wang C; Ho PC; Lim LY
Int J Pharm; 2010 Nov; 400(1-2):201-10. PubMed ID: 20804835
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
